Compass Therapeutics, Inc (CMPX)
2.12
0.00 (0.00%)
Upcoming Events
Latest Headlines
Leerink Assumes Compass Therapeutics (CMPX) at Outperform
July 21, 2026 4:49 PM - StreetInsider
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
July 17, 2026 10:42 AM - Globe NewsWire
Form 8-K Compass Therapeutics, For: Jul 01
July 1, 2026 5:01 PM - SEC Filing
Ladenburg Thalmann Assumes Compass Therapeutics (CMPX) at Buy
July 1, 2026 6:35 AM - StreetInsider
Form 8-K Compass Therapeutics, For: Jun 22
June 23, 2026 6:02 AM - SEC Filing
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
June 12, 2026 8:10 AM - StreetInsider
Form 8-K Compass Therapeutics, For: Jun 10
June 11, 2026 4:01 PM - SEC Filing
Compass Therapeutics (CMPX) Reiterated at Market Outperform by Citizens
June 4, 2026 5:22 AM - StreetInsider
Compass Therapeutics (CMPX) Reiterated at Buy by Stifel After ASCO Presentation
June 1, 2026 7:32 AM - StreetInsider
Compass Therapeutics to Participate in Upcoming June Investor Events
May 28, 2026 7:30 AM - Globe NewsWire
Compass Therapeutics reports phase 1 data for CTX-8371 at ASCO meeting
May 21, 2026 5:00 PM - StreetInsider
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
May 21, 2026 5:00 PM - Globe NewsWire
Form SCHEDULE 13G/A Compass Therapeutics, Filed by: BIOTECHNOLOGY VALUE FUND L P
May 15, 2026 4:12 PM - SEC Filing
Compass Therapeutics to Participate in Upcoming May Investor Events
May 12, 2026 7:30 AM - Globe NewsWire
Form 10-Q Compass Therapeutics, For: Mar 31
May 5, 2026 8:01 AM - SEC Filing
Compass Therapeutics, Inc. (CMPX) Reports In-Line Q1 EPS
May 5, 2026 7:47 AM - StreetInsider
Form 8-K Compass Therapeutics, For: May 05
May 5, 2026 7:30 AM - SEC Filing
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
May 5, 2026 7:30 AM - Globe NewsWire
Form 4/A Compass Therapeutics, For: Apr 29 Filed by: Lerner Neil
April 30, 2026 4:01 PM - SEC Filing
Form 4/A Compass Therapeutics, For: Apr 29 Filed by: Anderman Jonathan
April 30, 2026 4:01 PM - SEC Filing
Form 4 Compass Therapeutics, For: Apr 29 Filed by: Anderman Jonathan
April 29, 2026 5:12 PM - SEC Filing
Form 4 Compass Therapeutics, For: Apr 29 Filed by: Lerner Neil
April 29, 2026 4:59 PM - SEC Filing
Form ARS Compass Therapeutics, For: Dec 31
April 29, 2026 8:15 AM - SEC Filing
Form DEFA14A Compass Therapeutics,
April 29, 2026 8:09 AM - SEC Filing
Form DEF 14A Compass Therapeutics, For: Jun 10
April 29, 2026 8:09 AM - SEC Filing
Compass Therapeutics (CMPX) PT Lowered to $7 at Canaccord
April 28, 2026 6:49 AM - StreetInsider
Raymond James Downgrades Compass Therapeutics (CMPX) to Market Perform
April 28, 2026 6:24 AM - StreetInsider
Compass Therapeutics (CMPX) Reiterated at Market Outperform by Citizens on PFS, OS Results
April 28, 2026 4:16 AM - StreetInsider
Compass Therapeutics (CMPX) PT Lowered to $6 at Stifel
April 27, 2026 2:52 PM - StreetInsider
H.C. Wainwright on Compass Therapeutics (CMPX): 'we do believe the probability of a path forward is meaningfully higher than the market reaction observed'
April 27, 2026 11:50 AM - StreetInsider
Leerink on Compass Therapeutics (CMPX): 'there are multiple sources of long-term upside'
April 27, 2026 10:20 AM - StreetInsider
Stifel on Compass Therapeutics (CMPX): 'Path Forward Complicated by FDA’s “Imply-No-Harm” Mandate'
April 27, 2026 8:27 AM - StreetInsider
Compass Therapeutics stock plunges on trial data concerns, William Blair comments
April 27, 2026 8:15 AM - StreetInsider
William Blair on Compass Therapeutics (CMPX) 75% Drop: 'This will raise questions on the approvability of this dataset'
April 27, 2026 8:08 AM - StreetInsider
Form 8-K Compass Therapeutics, For: Apr 27
April 27, 2026 7:30 AM - SEC Filing
Compass Therapeutics drug shows progression-free survival benefit
April 27, 2026 7:30 AM - StreetInsider
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
April 27, 2026 7:30 AM - Globe NewsWire
Full Article List
